Legato Capital Management LLC Has $592,000 Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Legato Capital Management LLC grew its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 41.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,810 shares of the company’s stock after purchasing an additional 4,303 shares during the period. Legato Capital Management LLC’s holdings in Amphastar Pharmaceuticals were worth $592,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Principal Securities Inc. acquired a new position in Amphastar Pharmaceuticals in the 4th quarter worth about $34,000. YHB Investment Advisors Inc. acquired a new position in shares of Amphastar Pharmaceuticals during the 1st quarter valued at about $27,000. Quadrant Capital Group LLC increased its holdings in shares of Amphastar Pharmaceuticals by 27.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after acquiring an additional 223 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after acquiring an additional 309 shares during the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at about $93,000. 65.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on AMPH shares. Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Amphastar Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $63.00.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 3,596 shares of the firm’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at approximately $3,851,635.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Rong Zhou sold 4,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the completion of the sale, the executive vice president now owns 118,388 shares in the company, valued at $5,724,059.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO William J. Peters sold 3,596 shares of the business’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $40.93, for a total value of $147,184.28. Following the sale, the chief financial officer now owns 94,103 shares of the company’s stock, valued at approximately $3,851,635.79. The disclosure for this sale can be found here. Insiders sold 38,479 shares of company stock valued at $1,677,422 in the last three months. Corporate insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Trading Up 0.7 %

AMPH stock opened at $48.48 on Wednesday. The business has a fifty day moving average price of $41.53 and a 200 day moving average price of $43.19. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The stock has a market capitalization of $2.37 billion, a price-to-earnings ratio of 16.78, a P/E/G ratio of 0.75 and a beta of 0.79. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.18 and a quick ratio of 1.72.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.